Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasms × Asparaginase × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 46 Leukemia 34 Lymphoma 11 Lymphoma, Non-Hodgkin 5 Burkitt Lymphoma 4 Neoplasm, Residual 3 Myelodysplastic Syndromes 3 Leukemia, Myeloid, Acute 3 Leukemia, Biphenotypic, Acute 3 Dendritic Cell Sarcoma, Interdigitating 3 Anemia, Refractory, with Excess of Blasts 3 Recurrence 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Extranodal NK-T-Cell 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Monocytic, Acute 2 Leukemia, Erythroblastic, Acute 2 Leukemia, Eosinophilic, Acute 2 Anemia, Refractory 2 Thrombocytopenia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Neutropenia 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Myelomonocytic, Juvenile 1

Interventions

Gemcitabine 93 Paclitaxel 80 Carboplatin 72 Bevacizumab 72 Surveys and Questionnaires 63 Docetaxel 61 pembrolizumab 60 Cisplatin 59 Capecitabine 46 Exercise 44 Cyclophosphamide 43 Nivolumab 40 Sorafenib 38 Irinotecan 38 Fluorouracil 38 Pemetrexed 34 Dexamethasone 32 Blood Specimen Collection 31 Radiotherapy 29 Oxaliplatin 29 Leucovorin 28 Erlotinib Hydrochloride 28 Albumin-Bound Paclitaxel 28 Cetuximab 25 130-nm albumin-bound paclitaxel 25 Therapeutics 24 Doxorubicin 24 Methods 23 Ipilimumab 23 trametinib 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed

512 enrolled 19 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡